NASDAQ Uplisting
-
Exousia Pro Realigns Strategy, Acquires Controlling Stake in SEC-Reporter Lamy for Enhanced Growth
On November 17, 2025, Exousia Pro (MAJI) completed an all-stock deal, transferring its subsidiary Exousia AI to LAMY (LMMY) for roughly 51% of LMMY’s restricted common stock, making MAJI the controlling shareholder. MAJI also secured licensing fees and royalties related to exosome technology. LMMY will pursue a NASDAQ uplisting. Post-transaction, LMMY has 2,527,000 unrestricted shares, with 5,250,000 restricted shares unlocking in Q1 2026. MAJI may retain shares near-term and consider, in 2026, a share dividend.
